Federal lawmakers have renewed efforts to pass legislation ensuring Medicare coverage of multi-cancer early detection (MCED) tests.
Subscribe today for access to
Articles and Reports
Ruling could spell good news for labs and other healthcare providers targeted by whistleblowers in False Claims Act qui tam lawsuits.
Congress is renewing its previous efforts to make Medicare reimbursement of pharmacy testing permanent—here’s what that could mean for labs.
After it failed to pass at the end of 2022, lab leaders and other insiders say they’re optimistic SALSA will pass this year.
On March 28, the 118th Congress raised lab industry hopes once more by reintroducing the Saving Access to Laboratory Services Act (SALSA).
It’s not just billions of dollars on the line, but the very future of whistleblower lawsuits and FCA enforcement.
Resolution process put on hold after federal court again strikes down parts of the regulation as being unfairly weighted in favor of insurers.
Hopes are high that something will finally be done to resolve the LDTs situation this year, however that action may not come from Congress.
While the federal spending bill passed at the end of 2022 will have a large impact on clinical labs, it doesn’t include LDTs reform.
Legislation offering permanent relief from both PAMA price cuts and reporting didn’t make it into the federal spending bill passed Dec. 23.
With temporary waivers of restriction relating to telehealth likely to end soon, here’s a roundup of the current state of state telehealth licensing law.
Though Congress didn’t pass VALID as part of the medical devices user fees bill, there’s still a good chance it will pass before year’s end.
It remains far from clear whether the new surprise billing rule goes far enough to fix the problem of insurers having too much power in disputes.